Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($2.55), $0.98 worse than the analyst estimate of ($1.57). Revenue for the quarter came in at $1.93 million versus the consensus estimate of $6.05 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.